Ubiquitin-protein ligases--novel therapeutic targets?
Intracellular protein degradation is a tightly regulated process that in many cases is controlled by protein ubiquitylation. The ubiquitin pathway is a major route by which cells not only remove normal proteins at the appropriate time but also abnormally folded normal or mutant, cytoplasmic and membrane, proteins. This has led to a major impetus to identify constituents of the pathway. The key components that regulate substrate ubiquitylation are the ubiquitin-protein ligases. Ligases come in many forms, from single proteins to very large multiprotein complexes. Specificity of targeting can be modulated by the requirement for post-translational modifications such as phosphorylation, hydroxylation or oxidation of the substrate and, in some cases, the ligase itself. The requirement for substrate modification prior to ubiquitylation allows the same ligase to target different substrates within the same cell at different times. Abnormal intracellular protein processing is a common feature of many human diseases including neurodegenerative diseases and cancer. It may not represent the causative factor that initiates the disease process but may be a downstream regulator of the toxic effect. These abnormalities often arise from the loss of a key protein-protein interaction. As a consequence, mutated proteins can have very different half-lives from their normal counterparts. This can affect the levels of their activity and/or lead to the formation of protein aggregates (inclusion bodies/aggresomes). In this review, we aim to highlight examples of diseases where abnormal protein ubiquitylation is proposed to be a key regulator of the disease process. The recent success of the proteasome inhibitor Bortezomib (PS-341) for treatment of relapsed, refractory myeloma suggests that the modulation of individual ubiquitin-protein ligase activities with synthetic agents may represent a novel approach that has enormous potential for the treatment of a wide range of diseases.
Robinson
Philip A
PA
Molecular Medicine Unit, University of Leeds, Level 6 Clinical Sciences Building, St. James's University Hospital, Leeds LS9 7TF, UK. p.a.robinson@leeds.ac.uk
Ardley
Helen C
HC
D003546:Cysteine Endopeptidases / Q000378:metabolism*; D016503:Drug Delivery Systems; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D002479:Inclusion Bodies / Q000378:metabolism; D008107:Liver Diseases / Q000188:drug therapy* / Q000201:enzymology; D009097:Multienzyme Complexes / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000201:enzymology; D046988:Proteasome Endopeptidase Complex; D017510:Protein Folding; D044767:Ubiquitin-Protein Ligases / Q000037:antagonists & inhibitors / Q000378:metabolism*
D004791:Enzyme Inhibitors; D009097:Multienzyme Complexes; D044767:Ubiquitin-Protein Ligases; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex